TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00364611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (Avastin) 15 mg/kg will be administered prior to chemotherapy on~* On Day 1 of the 1st cycle over 120 minutes~* On Day 1 of the 2nd cycle over 90 minutes, if no reaction on the first dose~* On Day 1 of 3rd cycle over 60 minutes, if no reaction on previous doses~* On Day 1 of subsequent cycles over 30 minutes, if no reaction on previous doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (Avastin) 15 mg/kg will be administered prior to chemotherapy on~* On Day 1 of the 1st cycle over 120 minutes~* On Day 1 of the 2nd cycle over 90 minutes, if no reaction on the first dose~* On Day 1 of 3rd cycle over 60 minutes, if no reaction on previous doses~* On Day 1 of subsequent cycles over 30 minutes, if no reaction on previous doses
Study: NCT02452853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Description: FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin):~4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion. Repeated every 2 weeks
Study: NCT00364611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 IV infused over 60 minutes after completion of Bevacizumab infusion q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 IV infused over 60 minutes after completion of Bevacizumab infusion q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: * A loading dose of 8 mg/kg Trastuzumab (Herceptin) IV will be infused over 90 minutes on Day 2 of Cycle 1.~* For all subsequent cycles 6 mg/kg trastuzumab will be administered on Day 1 one hour following completion of docetaxel infusion
Study: NCT03244189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluid prescription
Description: The additional amount of fluid that the participant will need to consume each day, using the smart water bottle, in order to meet the study-specified urine output. This fluid is in addition to any other sources of fluid (ex. cups of coffee, bottled sports drink) that the participant consumes each day.
Study: NCT02278263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Given intravenously or topically

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline (0.9% NaCl)
Description: Administered in all 3 groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline (0.9% NaCl)
Description: Administered in all 3 groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline (0.9% NaCl)
Description: Administered in all 3 groups
Study: NCT02914860

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac CT
Description: * Cardiac CT - contract enhanced cardiac CT according to standard protocol~* D-SPECT SUMO study - standard SUMO protocol (suggested reduction in mIBG dose and increase in scan time to minimize overall radiation burden)~* Merge CT and D-SPECT image data to generate SUMO map.
Study: NCT03244189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Participants in the Intervention Arm who meet their fluid intake goal on randomly selected days will receive a small payment for that day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Problem Solving
Description: Structure Problem Solving involves interactions with health coaches to help participants develop feasible solutions to overcoming personal barriers to maintaining the prescribed fluid intake.
Study: NCT02862028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HerinCAR-PD1 cells
Description: herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
Study: NCT04214106

Intervention type: DRUG
Intervention: intravenous Thiamine
Description: patients who received Thiamine,100-500 mg/day for at least one day
Study: NCT02108795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Children randomised to remifentanil group receive remifentanil 0.05 ug/kg/min. Children randomised to control group receive normal saline (placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00883792

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Once-only colonoscopy screening
Study: NCT03411356

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Caloric Restriction (DCR)
Description: Participants in this group will be given a calorie goal designed to produce a 34.3% energy deficit from estimated baseline weight maintenance energy requirements. Participants in this group will also receive a 12 month comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support DCR. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting (IMF)
Description: Participants in this group will be instructed to limit energy intake to 20% of estimated baseline energy requirements on three non-consecutive days per week, and to eat ad libitum the other 4 days per week. Participants in this group will also receive a 12 month comprehensive group based behavioral weight loss program and will be instructed in specific strategies to support IMF. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
Study: NCT03018470

Intervention type: OTHER
Intervention: Analysis of data from NIV built-in software
Description: Analysis of breathing pattern using data obtained from NIV built-in software

Intervention type: OTHER
Intervention: Analysis of data from NIV built-in software
Description: Analysis of breathing pattern using data obtained from NIV built-in software
Study: NCT01008228

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exsufflation
Description: exsufflation will be performed with a specific thoracentesis system after introducing the device into chest pneumothorax, aspiration will be performed during 30 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic tube drainage
Description: thoracic tube drainage will be performed with a tube Ch 16 or ch 20
Study: NCT03018470

Intervention type: OTHER
Intervention: Analysis of data from NIV built-in software
Description: Analysis of breathing pattern using data obtained from NIV built-in software
Study: NCT02227589

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MET/CBT-12
Description: Two sessions of motivation enhancement therapy followed by 10 sessions of cognitive behavior therapy targeting alcohol or cannabis abuse. These 12 sessions will be delivered over 12 to 14 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET/CBT-12
Description: Two sessions of motivation enhancement therapy followed by 10 sessions of cognitive behavior therapy targeting alcohol or cannabis abuse. These 12 sessions will be delivered over 12 to 14 weeks.
Study: NCT00839865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: herb ointment
Description: a kind of ointment made from herb
Study: NCT05778773

Intervention type: PROCEDURE
Intervention: TAVR (Transcatheter Aortic Valve Replacement)
Description: Percutaneous aortic valve replacement, also known as percutaneous aortic valve implantation, transcatheter aortic valve implantation or transcatheter aortic valve replacement, is the replacement of the aortic valve of the heart through the blood vessels.
Study: NCT01714336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: Tranexamic acid will be administered intravenously in two doses of 15 mg/kg. Each dose will be administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A similar dose of 0.9% sodium chloride (NaCL) will be administered intravenously in two doses over a ten minute period, one dose at incision and the other at initiation of wound closure.
Study: NCT04433936

Intervention type: DIAGNOSTIC_TEST
Intervention: Pentacam tomography
Description: The Pentacam maps were analyzed. The following anterior and posterior corneal surface parameters were evaluated by the Scheimpflug system: Kf, Ks, Kmax. The pachymetric map was analyzed, including CCT at the apex of the geometric center and CTmin. PPIavg, PPI min and PPI max were calculated . The Ambrósio relational thickness (ART) was calculated The posterior corneal elevation maps were evaluated and the posterior corneal elevation values relative to this reference were recorded. The back difference elevation and multimetric D index values were extrapolated from the difference map of the Belin/Ambrósio-enhanced ectasia display of the Pentacam system.
Study: NCT02227589

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MET/CBT-12
Description: Two sessions of motivation enhancement therapy followed by 10 sessions of cognitive behavior therapy targeting alcohol or cannabis abuse. These 12 sessions will be delivered over 12 to 14 weeks.
Study: NCT03553264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Rehabilitation
Description: Track Speed Racing 3D game will run with HMD 'Revelation' 3D VR Headset and each HMD group patient will be instructed to perform the game protocol uninterruptedly for 20min/day, while sitting on a chair or sofa.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation
Description: The home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation
Description: The home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises
Study: NCT01631006

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: A low or high CPAP pressure is delivered for 20 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CPAP
Description: A low or high CPAP pressure is delivered for 20 minutes
Study: NCT01363154

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mozart K448
Description: Subjects will receive auditory stimulation by exposure to Mozart's Sonata for Two Pianos in D Major, K448.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Beethoven's Für Elise
Description: Subjects will receive auditory stimulation by exposure to Beethoven's Für Elise.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No music exposure
Description: Subject's will not receive an intervention and will therefore, not receive auditory stimulation and/or exposure to music.
Study: NCT03042728

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dog Interaction
Description: A therapy dog will visit the patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Interaction
Description: A human will visit the patients.
Study: NCT03763292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific information brochure
Description: A purpose-designed brochure about anesthesia and surgery in the ear in children is developed by the investigators. This brochure has photos and describes the procedures the child is going through.
Study: NCT02227589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-D
Description: CBT-D consists of seven weekly sessions of cognitive behavior therapy targeting depression.
Study: NCT05778773

Intervention type: PROCEDURE
Intervention: AVR (Aortic Valve Replacement)
Description: Aortic valve replacement is a procedure whereby the failing aortic valve of a patient's heart is replaced with an artificial heart valve through an open-heart surgery.
Study: NCT02914860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac CT
Description: * Cardiac CT - contract enhanced cardiac CT according to standard protocol~* D-SPECT SUMO study - standard SUMO protocol (suggested reduction in mIBG dose and increase in scan time to minimize overall radiation burden)~* Merge CT and D-SPECT image data to generate SUMO map.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation Procedure
Description: 1. CARTO-reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO.~2. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline).~3. RF ablation only at points where there is an HFS positive response to SUMO DUA (in sinus rhythm if AF converts)~4. Target a region of 1.0 - 1.5 cm diameter around the SUMO mIBG DUA~5. Control HFS~6. At operator discretion, conventional PVI by circumferential antral ablation according to standard procedures.~7. Exit and entrance block confirmation~8. Attempt to induce sustained atrial tachycardia; optional mapping and ablation of post-ablation atrial tachycardia.
Study: NCT03871452

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ankaferd Blood Stopper in theTraumatic Bleeding
Description: ankaferd blood stpper They were trained to apply compression of approximately 3-kg weight after irrigation with saline in patients with active bleeding who met inclusion criteria. Bleeding was controlled in every minute and data were collected. Traditional methods such as primary suturing were performed in patients whose bleeding did not stop within 10 minutes. Patients whose bleeding was stopped were monitored for half an hour for bleeding recurrence.~The patients were divided into two groups; ones treated by ABS soaked wet compresses (group I) and ones treated by dry sponge compresses

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ankaferd Blood Stopper in theTraumatic Bleeding
Description: ankaferd blood stpper They were trained to apply compression of approximately 3-kg weight after irrigation with saline in patients with active bleeding who met inclusion criteria. Bleeding was controlled in every minute and data were collected. Traditional methods such as primary suturing were performed in patients whose bleeding did not stop within 10 minutes. Patients whose bleeding was stopped were monitored for half an hour for bleeding recurrence.~The patients were divided into two groups; ones treated by ABS soaked wet compresses (group I) and ones treated by dry sponge compresses
Study: NCT03425721

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention is administered in this study.
Study: NCT01300819

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patches of 2, 4, 6 \& 8 mg / 24 hours Daily application of Placebo patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose was 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day.
Study: NCT02914860

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation Procedure
Description: 1. CARTO-reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO.~2. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline).~3. RF ablation only at points where there is an HFS positive response to SUMO DUA (in sinus rhythm if AF converts)~4. Target a region of 1.0 - 1.5 cm diameter around the SUMO mIBG DUA~5. Control HFS~6. At operator discretion, conventional PVI by circumferential antral ablation according to standard procedures.~7. Exit and entrance block confirmation~8. Attempt to induce sustained atrial tachycardia; optional mapping and ablation of post-ablation atrial tachycardia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation Procedure
Description: 1. CARTO-reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO.~2. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline).~3. RF ablation only at points where there is an HFS positive response to SUMO DUA (in sinus rhythm if AF converts)~4. Target a region of 1.0 - 1.5 cm diameter around the SUMO mIBG DUA~5. Control HFS~6. At operator discretion, conventional PVI by circumferential antral ablation according to standard procedures.~7. Exit and entrance block confirmation~8. Attempt to induce sustained atrial tachycardia; optional mapping and ablation of post-ablation atrial tachycardia.
Study: NCT02227589

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D-TAU
Description: D-TAU is treatment as usual in the community, targeting depression. It may consist of medication and/or behavioral intervention.
Study: NCT02248610

Intervention type: OTHER
Intervention: Non-interventional study
Study: NCT03108027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
Description: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
Description: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
Description: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
Description: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
Description: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
Description: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
Description: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
Description: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
Description: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
Study: NCT02914860

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: D-SPECT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: D-SPECT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: D-SPECT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: D-SPECT
Study: NCT02600533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video viewing group
Description: First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
Study: NCT01269541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin
Description: Topical in the nose 3 times daily for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin+Clindamycine or Trimehoprimsulfa
Description: Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin+Clindamycine or Trimehoprimsulfa
Description: Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2
Study: NCT01300819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine patches of 2, 4, 6, and 8 mg / 24 hours~Once daily application of Rotigotine patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose is 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day.
Study: NCT04347980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone and Hydroxychloroquine
Description: Patients included in the Hydroxychloroquine / Dexamethasone group will benefit from standardized ventilatory management and administration of Hydroxychloroquine in the same manner as the Hydroxychloroquine group. They will receive in addition to Dexamethasone at a rate of 20 mg intravenously for 15 min once a day for 5 days (D1 to D5) then at a rate of 10 mg per day from D6 to D10. If the patient is extubated before the 10th day, he will receive his last dose of Dexamethasone before.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Patients included in the Hydroxychloroquine group will benefit from standardized ventilatory management. Patients included in the Hydroxychloroquine group will receive 200 mg x 3 / day enterally from J1 of the HCQ for 10 days. If the patient is extubated before the 10th day, he will receive his last dose of HCQ before.
Study: NCT01476280

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: palonosetron
Description: 0.075mg immediately before induction of anesthesia

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ramosetron
Description: 0.3mg immediately before induction of anesthesia